Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of “Hold” from Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been assigned a consensus rating of “Hold” from the thirteen brokerages that are currently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $42.09.

Several research analysts have commented on KYMR shares. Oppenheimer restated an “outperform” rating and set a $52.00 price objective on shares of Kymera Therapeutics in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $46.00 price objective on shares of Kymera Therapeutics in a research report on Monday, June 17th. Finally, B. Riley boosted their price objective on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday.

Kymera Therapeutics Trading Up 7.6 %

NASDAQ KYMR opened at $39.00 on Friday. Kymera Therapeutics has a 1-year low of $9.60 and a 1-year high of $45.31. The company has a 50 day moving average of $33.84 and a 200-day moving average of $34.66. The company has a market cap of $2.39 billion, a price-to-earnings ratio of -15.54 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. The company had revenue of $10.30 million during the quarter, compared to the consensus estimate of $14.24 million. During the same period in the previous year, the business earned ($0.70) earnings per share. The firm’s quarterly revenue was up 8.4% on a year-over-year basis. On average, equities research analysts forecast that Kymera Therapeutics will post -2.86 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Bruce Booth sold 453,960 shares of the business’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total value of $17,345,811.60. Following the sale, the director now owns 723,246 shares of the company’s stock, valued at $27,635,229.66. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Joanna Horobin sold 8,500 shares of the business’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $32.99, for a total value of $280,415.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bruce Booth sold 453,960 shares of the business’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the completion of the sale, the director now directly owns 723,246 shares in the company, valued at approximately $27,635,229.66. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 479,200 shares of company stock valued at $18,219,660. 15.82% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of KYMR. Hsbc Holdings PLC acquired a new position in Kymera Therapeutics in the third quarter valued at $185,000. GSA Capital Partners LLP lifted its holdings in Kymera Therapeutics by 141.2% in the third quarter. GSA Capital Partners LLP now owns 51,088 shares of the company’s stock valued at $710,000 after buying an additional 29,904 shares during the period. Vanguard Group Inc. lifted its holdings in Kymera Therapeutics by 4.9% in the third quarter. Vanguard Group Inc. now owns 3,925,213 shares of the company’s stock valued at $54,560,000 after buying an additional 182,125 shares during the period. Exchange Traded Concepts LLC lifted its holdings in Kymera Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,359 shares of the company’s stock valued at $187,000 after buying an additional 1,866 shares during the period. Finally, SG Americas Securities LLC acquired a new position in Kymera Therapeutics in the fourth quarter valued at $473,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.